-
1.发明申请
公开(公告)号：WO2023091793A1
公开(公告)日：2023-05-25
申请号：PCT/US2022/050759
申请日：2022-11-22
IPC分类号： A61K31/497 , A61K31/435 , A61K31/506 , A61K31/519 , A61K39/395
摘要： It was found that FLT3-associated diseases could be treated by exposing an abnormal cell to a FLT3 inhibitor, wherein the method further comprises exposing the abnormal cell to a composition which promotes reactivation of glycolysis of the cell. Also contemplated are compositions for treating FLT3-associated disease, the composition comprising a combination of a reactivator of glycolysis and an inhibitor of FLT3.
-
公开(公告)号：WO2023088385A1
公开(公告)日：2023-05-25
申请号：PCT/CN2022/132632
申请日：2022-11-17
申请人： 浙江同源康医药股份有限公司
IPC分类号： C07D401/12 , C07D417/12 , C07D401/02 , C07D401/14 , A61K31/427 , A61K31/496 , A61K31/506
摘要： 本发明涉及用于EGFR蛋白降解的化合物及其用途。具体地，本发明涉及式(I)所示化合物，其中各基团和取代基的定义如说明书中所述。本发明还涉及所述化合物在制备用于调节EGFR酪氨酸激酶活性或治疗EGFR相关疾病，尤其是非小细胞肺癌的药物方面的应用。
-
公开(公告)号：WO2023087027A1
公开(公告)日：2023-05-19
申请号：PCT/US2022/079896
申请日：2022-11-15
申请人： ERASCA, INC.
IPC分类号： A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/5513 , A61K31/553 , A61K31/554 , A61P35/00 , C07D409/04 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D497/04 , C07D498/04 , C07D513/04 , C07D515/04 , C07D519/00 , C07F9/6558 , C07D487/08 , C07D495/04
摘要： Described herein are compounds that are ULK1/2 inhibitors and their use in the treatment of disorders such as cancers.
-
4.发明申请
公开(公告)号：WO2023086561A1
公开(公告)日：2023-05-19
申请号：PCT/US2022/049690
申请日：2022-11-11
申请人： TERNS PHARMACEUTICALS, INC. , FENAUX, Martijn , KLUCHER, Kevin , JONES, Christopher T. , KIRSCHBERG, Thorsten A. , WANG, Yujin
发明人： FENAUX, Martijn , KLUCHER, Kevin , JONES, Christopher T. , KIRSCHBERG, Thorsten A. , WANG, Yujin
摘要： Provided herein are methods for treating liver disorders, including non-alcoholic steatohepatitis (NASH), and symptoms and manifestations thereof, in a patient which utilize, among others, a combination treatment of an SSAO inhibitor and a THR-β agonist. Also provided are fixed-dose combinations of an SSAO inhibitor and a THR-β agonist for use in treating NASH.
-
公开(公告)号：WO2023081232A1
公开(公告)日：2023-05-11
申请号：PCT/US2022/048739
申请日：2022-11-02
发明人： LI, Richard, Hui , LEE, Dong, Jun , CHU-KUNG, Alexander, Fann-yan , NYE, Erin, Morgan , MAHLOCH, Alexis, Brooke
IPC分类号： A61K31/4427 , A61K31/44 , A61K31/505 , A61K31/506 , C07D213/04 , C07D253/02 , C07D253/06
摘要： The invention provides novel linkers, linker conjugates, and drug conjugates thereof comprising a targeting moiety, a linker moiety, and a drug moiety, wherein the drug moiety is conjugated to the linker which is conjugated to the targeting moiety, as well as methods of preparation and use thereof for treating various diseases and conditions.
-
公开(公告)号：WO2023080732A1
公开(公告)日：2023-05-11
申请号：PCT/KR2022/017291
申请日：2022-11-04
申请人： 주식회사 유빅스테라퓨틱스
IPC分类号： C07D401/14 , C07D471/04 , A61K31/506
摘要： 본 개시는 BTK를 분해하는 측면에서 우수한 활성을 갖는 특정 화학구조의 화합물 또는 이의 약학적으로 허용 가능한 염을 제공한다. 본 개시는 또한 이러한 화합물 또는 이의 약학적으로 허용 가능한 염을 포함하는 조성물을 제공한다. 본 개시는 또한 본 개시에 따른 화합물, 이의 염 및 이들을 포함하는 조성물의 BTK 관련 질환(예를 들어, 자가면역질환 또는 암)의 치료 또는 예방용 의약 용도를 제공한다. 본 개시는 또한 본 개시에 따른 화합물, 이의 염 또는 이들을 포함하는 조성물의 유효한 양을 치료가 필요한 개체에게 투여하는 것을 포함하는 BTK 관련 질환(예를 들어, 자가면역질환 또는 암)의 치료 또는 예방 방법을 제공한다.
-
公开(公告)号：WO2023079132A1
公开(公告)日：2023-05-11
申请号：PCT/EP2022/080933
申请日：2022-11-07
申请人： CELLESTIA BIOTECH AG
IPC分类号： A61K31/436 , A61K31/44 , A61P35/00 , A61K31/4375 , A61K31/4545 , A61K31/4745 , A61K31/4985 , A61K31/506 , A61K31/52 , A61K31/5377
摘要： The present invention relates to pharmaceutical combinations comprising a kinase inhibitor and a NOTCH signaling pathway inhibitor and their use in a method for the prevention, delay of progression or treatment of cancer in a subject.
-
公开(公告)号：WO2023073134A2
公开(公告)日：2023-05-04
申请号：PCT/EP2022/080136
申请日：2022-10-27
申请人： ASSOCIATION INSTITUT DE MYOLOGIE , SORBONNE UNIVERSITE , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
IPC分类号： A61K31/506 , A61K31/00 , A61K31/36 , A61K31/4025 , A61K31/405 , A61K31/422 , A61K31/496 , A61K31/505 , A61K45/06 , A61K48/00 , A61P21/00 , G01N33/74 , G01N33/68 , A01K67/027 , A01K2207/12 , A01K2207/15 , A01K67/0271 , G01N2333/5754 , G01N2800/52 , G01N2800/7052 , G01N33/6893
摘要： The present invention concern endothelin receptor antagonists for use in the treatment or the prevention of muscle fibrosis.
-
9.发明申请
公开(公告)号：WO2023068858A1
公开(公告)日：2023-04-27
申请号：PCT/KR2022/016095
申请日：2022-10-20
发明人： KIM, Ji Sook , CHOI, Jae Yul , AHN, Young Gil
IPC分类号： A61K31/506 , A61K31/496 , A61K31/635 , A61K31/706 , A61K31/704 , A61K45/06 , A61P35/02
摘要： This invention relates to pharmaceutical compositions, pharmaceutical combinations and methods for the treatment of acute myeloid leukemia by combined use of a therapeutically effective combination of a compound of Chemical Formula 1, or a pharmaceutically acceptable salt thereof, solvate thereof, stereoisomer thereof, tautomer thereof, or combination thereof, wherein Ea, Eb, Ec, Ed, Z', X', Q, and k are defined herein; and a Bcl-2 inhibitor, or a Bcl-2 inhibitor and a hypomethylating agent.
-
公开(公告)号：WO2023060362A1
公开(公告)日：2023-04-20
申请号：PCT/CA2022/051520
申请日：2022-10-14
申请人： GENETOLEAD INC.
发明人： FARMER, Luc , LAPLANTE, Steven , AYOTTE, Yann , LARDA, Sacha Thierry , ALAPOUR, Saba , WOO, Simon , BENDAHAN, David , DENK, Maria , FARAHANI, Majid , IDDIR, Mustapha
IPC分类号： C07D209/18 , A61K31/404 , A61K31/405 , A61K31/454 , A61K31/496 , A61K31/506 , A61K31/4045 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K31/5386 , C07D209/14 , C07D401/04 , C07D401/06 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/12 , C07D413/06 , C07D491/107
摘要： There is provided a compound of formula (I), and its use for inhibiting RAS (wild type or mutant), for example HRAS, NRAS, and/or KRAS, and for the prevention or treatment of a disease or disorder associated with abnormal RAS activity, for example abnormal RAS activity caused by a mutation in RAS, including cancers with a mutated RAS. (I)
-
-
-
-
-
-
-
-
-
搜索结果
6997 条记录 (耗时 0.067 秒)
